Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Generic Drugs: First-Cycle Review Times Improve, But Hundreds Of ANDAs Still Pending

Jul 04 2017

• By Derrick Gingery

FDA entrance sign 2016

Related Content

ANDA Reviews: First-Cycle Desired, But Two-Cycles OK?

Jul 27 2015

Generic Drug First-Cycle Approval Rates Lagging Under GDUFA I

Oct 26 2016

Generic Drug Sponsors Seek Advance Notice Of Approvals From US FDA

May 17 2017

ANDA Approval Times Get Optimistic Estimate In Budget Request

May 26 2017

GDUFA Performance Goals For Fiscal Years 2013-2017

Dec 12 2011

ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal

Sep 24 2016

Generic User Fees: FDA Goes On Backlog Offensive

Oct 16 2015

FDA Drug Pricing Policy Offers Short-Term PR Gain, More Long-Term Actual Benefit

Jun 28 2017

Additional Topics

United States Generic Drugs Review Pathway Regulation Approvals FDA BioPharmaceutical

More from Generics

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window